Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Ratios and Metrics

Market cap in millions USD. Fiscal year is September - August.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 25, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Market Capitalization	24	62	8	18	35	31
Market Cap Growth	-35.60%	627.66%	-51.77%	-50.18%	13.53%	-42.60%
Enterprise Value	20	53	5	10	27	29
Last Close Price	1.08	3.91	1.05	2.96	6.22	10.38
PS Ratio	29.87	133.15	37.56	68.97	48.92	98.93
PB Ratio	3.80	8.07	3.17	2.31	2.71	12.55
P/TBV Ratio	4.77	8.22	3.29	2.36	2.74	13.95
EV/Sales Ratio	31.68	114.33	21.58	39.44	37.19	92.55
Debt / Equity Ratio	0.02	0.02	0.06	0.01	0.01	0.06
Asset Turnover	0.07	0.08	0.04	0.02	0.09	0.11
Inventory Turnover	-	-	-	2.11	2.39	0.81
Quick Ratio	3.35	6.10	5.99	32.79	78.90	7.20
Current Ratio	3.90	7.18	8.04	35.96	81.18	8.53
Return on Equity (ROE)	-152.89%	-112.36%	-130.18%	-71.35%	-73.16%	-166.85%
Return on Assets (ROA)	-84.74%	-59.56%	-73.59%	-39.21%	-44.17%	-94.23%
Return on Capital (ROIC)	-93.60%	-66.91%	-76.32%	-39.70%	-44.99%	-101.11%
Return on Capital Employed (ROCE)	-216.30%	-73.30%	-228.20%	-86.60%	-43.40%	-159.40%
Earnings Yield	-47.42%	-9.38%	-78.45%	-41.27%	-11.39%	-12.63%
FCF Yield	-40.66%	-8.09%	-69.63%	-27.98%	-11.28%	-8.41%
Buyback Yield / Dilution	-62.48%	-87.24%	-12.38%	-34.02%	-58.34%	-6.95%

Updated May 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q